Related Experiment Video
Updated: Aug 24, 2026

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
Published on: October 12, 2012
Low- and ultra-low-molecular-weight heparins
1Department of Surgical Oncology and Technology, Faculty of Medicine, Imperial College, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK. akkakkaar@tri-london.ac.uk
Abstract:
Heparins and low-molecular-weight heparins (LMWHs) have been the mainstay for the prevention and management of venous and arterial thromboembolic disease. In particular, the LMWHs have become well established in the past 15 years for the prevention of thrombosis in medium- and high-risk surgical and medical patients and in the initial management of venous thromboembolism (VTE). They have also been widely evaluated and adopted in clinical practice in the management of patients with acute coronary syndromes. More recently, a variety of heparin-like drugs have been evaluated as potential antithrombotic agents, and the synthetic pentasaccharide (fondaparinux) has been developed and evaluated for the prevention and treatment of VTE.
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Venous Thrombosis III: Interprofessional Care
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Local Anesthetics: Clinical Application as Intravenous Regional Anesthesia
One of the advantages of...
Drug Distribution: Volume of Distribution

